Fosamax (alendronate) will soon be promoted to PREVENT osteoporosis in postmenopausal women
April 1997
Fosamax (alendronate) will soon be promoted to PREVENT osteoporosis in postmenopausal women.
It was originally approved just for treatment.
Fosamax slows bone loss and increases bone density. It reduces hip fractures by 50% in women who already have osteoporosis.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote